Exhibit 99.1 Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights "The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious diseases. The additional approval for TEPKINLY, along with positive data presentations for our promising late-stage assets acasunlim ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapyGenmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimabGenmab revenue inc ...

Company Performance - Worldwide net trade sales of DARZALEX® in Q3 2024 totaled USD 3,016 million, with USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world [1] - Genmab receives royalties on worldwide net sales of DARZALEX®, including both intravenous and subcutaneous products, under an exclusive license to Janssen Biotech, Inc [1] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives [2] - The company has a 25-year history of inventing next-generation antibody technology platforms, including bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators [2] - Genmab's vision is to transform the lives of people with cancer and serious diseases by 2030 through its KYSO® antibody medicines [2] Corporate Structure - Genmab was established in 1999 and is headquartered in Copenhagen, Denmark [3] - The company has an international presence across North America, Europe, and Asia Pacific [3]

Company Announcement - Genmab A/S announces that Baillie Gifford & Co holds voting rights to 3,301,530 shares, representing 4.99% of the share capital and voting rights as of October 3, 2024 [1] About Genmab - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform cancer treatment by 2030 [2] - The company has developed next-generation antibody technology platforms, including bispecific T-cell engagers and antibody-drug conjugates, leveraging data sciences for its proprietary pipeline [2] Company Background - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with a presence in North America, Europe, and Asia Pacific [3]

Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy COPENHAGEN, Denmark; August 19, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the trea ...

Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2024 August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights "In the second quarter of 2024, we reached a number of significant milestones for the company. The acquisition of ProfoundBio, along with the regulatory approvals for EPKINLY and Tivdak, further solidify our commitment to the development of differentiated antibody therapies and will advance Genmab towards our ambitious 2030 visi ...

Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreement The overall collaboration between the companies to continue unchanged COPENHAGEN, Denmark; August 5, 2024 – Genmab A/S (NASDAQ:GMAB) announced today that it will assume sole responsibility for the continued development and potential ...

The biotechnology industry had a rough first-half 2024 after a decent performance in 2023. The majority of biotech players do not generate enough revenues to fund their operations and are dependent on external funds. A biotech company starts generating revenues following a successful FDA approval and the launch of any drug. Under this circumstance, a high interest rate regime is detrimental to the biotech industry. The primary reason for the industry's weak performance year to date is that the Fed refrained ...

"Many people living with follicular lymphoma that has either relapsed or is refractory to existing therapies experience significant treatment challenges with poor prognosis," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "This positive opinion recognizes the unmet need in the European Union for patients whose follicular lymphoma is considered difficult-to-treat and that epcoritamab may represent a new therapeutic option." Positive CHMP opinion based on results from the Phase 1/2 EPCORE® ...

Company Announcement COPENHAGEN, Denmark; June 28, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization of epcoritamab (TEPKINLY®), a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or ...